Skip to main content
Smart Investors Daily
RD

NYSE · RDY

Dr. Reddy's Laboratories Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$14.70

Down-$0.04 (-0.27%)

Updated Nov 17, 2026, 11:19 AM

SID Score

6.6/10

Composite research score

Smart Money

58/100

Neutral

Market cap
11.73B
P/E ratio
18.22
Dividend yield
0.62%
52-week range
$11.36 – $15.67
Volume
1.23M
Avg. volume
1.06M

Price performance · RDY

RDY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

RDY closed at $14.70 after 21 trading sessions, up 12.39% for the selected period.

Last close
$14.70
Period change
+12.39%
Period low
$13.08
Period high
$15.05
Daily close
View OHLC price history
RDY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$14.81$14.875$14.67$14.701.23M
Nov 13, 2026$14.73$14.87$14.64$14.743.71M
Nov 12, 2026$14.85$14.935$14.73$14.731.65M
Nov 11, 2026$14.67$14.84$14.605$14.842.18M
Nov 10, 2026$14.94$15.03$14.86$14.861.8M
Nov 9, 2026$14.91$15.08$14.7988$15.052.59M
Nov 6, 2026$14.43$14.91$14.35$14.912.64M
Nov 5, 2026$14.68$14.795$14.47$14.534.81M
Nov 4, 2026$14.49$14.785$14.48$14.772.12M
Nov 3, 2026$14.26$14.42$14.23$14.302.66M
Nov 2, 2026$14.15$14.195$14.05$14.131.93M
Oct 30, 2026$14.20$14.31$14.15$14.171.83M
Oct 29, 2026$14.19$14.33$14.095$14.112.11M
Oct 28, 2026$13.88$14.2387$13.69$14.154.47M
Oct 27, 2026$13.62$13.855$13.62$13.754.58M
Oct 26, 2026$13.595$13.855$13.595$13.754.12M
Oct 23, 2026$13.52$13.57$13.175$13.213.91M
Oct 22, 2026$13.11$13.29$13.055$13.233.98M
Oct 21, 2026$13.24$13.24$13.15$13.192.11M
Oct 20, 2026$13.21$13.35$13.175$13.264.23M
Oct 19, 2026$13.05$13.12$13.015$13.081.5M

Latest RDY news

The latest Smart Investors Daily articles mentioning RDY.

RDY research

Overview

Company profile and research snapshot.

Company profile

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
RDY recent ratings
DateFirmRatingTarget
Sep 6, 2021SharekhanBuy—
Jul 28, 2021Prabhudas LilladherAccumulate—
Jul 28, 2021Axis DirectBuy—
Jul 28, 2021ICICI Securities LimitedHold—
Jul 28, 2021Motilal OswalNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.